Industry Watch [to 6 December 2014]
:: Pfizer Completes Acquisition of Baxter’s Marketed Vaccines
December 01, 2014
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced that it has completed the acquisition of Baxter International Inc.’s portfolio of marketed vaccines. The portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac. As previously announced, Pfizer also acquired a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured…

NeisVac-C is a vaccine that helps protect against meningitis caused by group C meningococci(MenC)…MenC is one of the most prevalent meningococcal serogroups in many parts of the world and vaccination with NeisVac-C has been shown to be highly effective.

FSME-IMMUN/TicoVac is a vaccine that helps protect against tick-borne encephalitis (TBE), an infection of the brain, which is transmitted by the bite of ticks infected with the TBE-virus… FSME-IMMUN/TicoVac is approved in 30 countries and has been marketed for over 30 years with approximately 120 million doses produced since 1976….